A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986036 in Participants With Varying Degrees of Renal Function
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Pegbelfermin (Primary)
- Indications Fibrosis; Liver disorders; Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 04 Oct 2019 Status changed from active, no longer recruiting to completed.
- 26 Jun 2019 Planned End Date changed from 2 May 2019 to 23 Aug 2019.
- 26 Jun 2019 Planned primary completion date changed from 2 May 2019 to 23 Aug 2019.